sb 202190 has been researched along with Acute Brain Injuries in 1 studies
4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)imidazole: structure given in first source; inhibits p38 MAP kinase
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Li, P | 1 |
| Li, X | 1 |
| Deng, P | 1 |
| Wang, D | 1 |
| Bai, X | 1 |
| Li, Y | 1 |
| Luo, C | 1 |
| Belguise, K | 1 |
| Wang, X | 1 |
| Wei, X | 1 |
| Xia, Z | 1 |
| Yi, B | 1 |
1 other study available for sb 202190 and Acute Brain Injuries
| Article | Year |
|---|---|
Activation of adenosine A3 receptor reduces early brain injury by alleviating neuroinflammation after subarachnoid hemorrhage in elderly rats.
Topics: Adenosine A3 Receptor Agonists; Adenosine A3 Receptor Antagonists; Animals; Brain; Brain Injuries; C | 2020 |